For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- M3 to Make Mediscience Planning Its Wholly Owned Subsidiary
December 6, 2013
- Takeda Offered 600 M. Yen in Grants to Kyoto University Involved in CASE-J Study, Where Ex-Employee Affiliated
December 5, 2013
- Takeda to Market Teva’s Multiple Sclerosis Treatment in Japan
December 5, 2013
- Sawai President Requests Cautious Discussions on Generic Prices, Shows Confidence in Surviving
December 5, 2013
- “Big Gap” Remains to Reach 5-Year Profit Target: Astellas Pres.
December 5, 2013
- DSP, Healios Tie Up, Aim to Launch iPS Products in 2018
December 4, 2013
- Ono Joins SGLT-2 Inhibitor Battle via Copromotion Deal with AstraZeneca
December 4, 2013
- Eisai Shakes Up R&D Organization, Paring 130 Jobs in US, Europe
December 4, 2013
- Eisai to Transfer Business Operations at Misato Plant to Bushu Pharmaceuticals
December 4, 2013
- Bayer HealthCare Files Eylea for mCNV in Japan
December 4, 2013
- Reimbursement Listing of Ipragliflozin Expected in April; 4 Rival SGLT-2 Inhibitors Seen to Follow Suit 1 Month Later
December 3, 2013
- Takeda Ready to Welcome Foreign Exec with Open Arms as Company Leader
December 3, 2013
- Japan Gardasil Sales Dive 49.6% in January-September
December 3, 2013
- Merck to Shed 200 Jobs in Japan by 2015
December 3, 2013
- Eisai to Offer Voluntary Retirement Program in Japan
December 3, 2013
- Takeda President Calls GSK Weber Competitive Global Talent, Pushes Globalization
December 2, 2013
- Eisai Files for Approval of Pariet for Preventing Recurrent Ulcers during Aspirin Therapy
December 2, 2013
- GSK Exec Tapped as Takeda’s Next President, 1st Non-Japanese to Lead Japan Juggernaut
December 2, 2013
- AnGes MG to Resume Collategene Development for Critical Limb Ischemia Treatment: President Yamada
November 29, 2013
- No Mortality Cases Reported in Association with Eliquis at PMS: BMKK/Pfizer Japan
November 29, 2013
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…